Clinical Trials Directory

Trials / Unknown

UnknownNCT04512898

Helicobacter Pylori Eradication and Irritable Bowel Syndrome: A Prospective Study

Effect of Helicobacter Pylori Eradication on Symptoms and Quality of Life of Irritable Bowel Syndrome: A Prospective Study

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

H. Pylori is frequently observed in patients with irritable bowel syndrome(IBS). However, the effect of H. pylori eradication on IBS is not clear.

Detailed description

Patients with IBS symptoms using Rome IV criteria will be included. Testing for H. pylori will be done. Patients with H. pylori will receive triple therapy and followed after two weeks for eradication and assessment of IBS symptoms.

Conditions

Interventions

TypeNameDescription
DRUGTriple therapy for H.pyloriTriple therapy of proton pump inhibitors, clarithromycin and metronidazole.

Timeline

Start date
2020-08-10
Primary completion
2020-11-10
Completion
2020-11-10
First posted
2020-08-14
Last updated
2020-08-14

Source: ClinicalTrials.gov record NCT04512898. Inclusion in this directory is not an endorsement.

Helicobacter Pylori Eradication and Irritable Bowel Syndrome: A Prospective Study (NCT04512898) · Clinical Trials Directory